U.S. Markets closed

Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval

Allison DeAngelis
Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval

Biogen has new competition: Swiss pharma giant Novartis received FDA approval Friday for a spinal muscular atrophy drug that can stave off and potentially cure the disease with a single treatment.